Full-Time

NPI Manufacturing Engineering Manager

Posted on 12/10/2025

Deadline 12/19/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$114k - $197.2k/yr

San Jose, CA, USA

In Person

Willing to travel 10-20% domestically and internationally.

Category
Mechanical Engineering (1)
Requirements
  • A Bachelor’s degree in Engineering or related field; Mechanical, Biomedical, or Mechatronics is preferred.
  • Minimum of 8+ years of relevant professional experience.
  • Minimum of 2+ years of work experience as a people leader developing direct reports.
  • Manufacturing engineer background with end-to-end equipment development experience to provide guidance and mentorship.
  • Experience in medical device manufacturing is required.
  • Knowledge of good manufacturing practices and documentation for production processes is required.
  • Statistical Process Control knowledge and management of statistical procedures is required.
  • Knowledge of Microsoft Office, SAP, Jira, Teams, and Minitab is required.
  • Comprehension of engineering design documentation and drawing specification understanding as it relates to process controls; specifically at the component and fixture level for identifying key drawing features to support design for manufacturability and assembly for new product introductions in accordance with regulatory, industry, and Johnson & Johnson standards is required.
  • Ability and willingness to be based in San Jose, California and travel 10-20% domestic and international.
  • Green Belt certification is required; Black Belt certification is preferred.
  • Experience with Design of Experiments is preferred.
Responsibilities
  • Provides day-to-day tactical engineering direction and guidance for engineering associates supporting manufacturing to ensure short and long-term goals are met.
  • Primary lead contact for Operations, Packaging, Processing & Labeling, Quality Assurance, Research and Development, Program Management, New Product Introduction as needed to achieve company goals and objectives.
  • Provides training, guidance, coaching, performance appraisals, mentoring and career development for engineers.
  • Owns the successful implementation of new technology, processes and systems as well as continuous improvement to existing processes and technology.
  • Grow the NPI team’s capabilities by developing existing talent and hiring new talent.
  • Build strong teams through trust and mentorship.
  • Develop NPI in the business and partner with leaders in other engineering teams, design, and product management to champion a shared advanced manufacturing vision.
  • Craft data-driven strategies and action plans to deliver improvements to manufacturing processes.
  • Ensure work produced by the team follows industry-standard research methodologies and processes.
  • Identify, design, and develop equipment related to new product development.
  • Prepare and deliver process and test specifications.
  • Purchase and design equipment that meets Johnson & Johnson standards of safety and environment requirements.
  • Develop new manufacturing and assembly processes consistent with design for manufacturability and assembly for new product introductions in accordance with regulatory, industry, and Johnson & Johnson standards.
  • Continuously seek automation opportunities to reduce costs and improve quality.
  • Coordinate and perform qualification of new and improved manufacturing equipment and automation systems.
  • Coordinate and technically support the work of engineers and technicians.
  • Communicate business-related issues or opportunities to the next management level.
  • Provide problem-solving and technical assistance to manufacturing engineers and operations to resolve process control issues.
  • Partner multi-functionally to meet business objectives, including quality, financial, environmental health and safety, and performance goals.
  • Evaluate new technologies to improve process safety, quality, reliability, and efficiency; implement digital solutions to solve problems and enhance process performance.
  • Coordinate training of personnel on equipment operation and maintenance.
  • Submit Capital Appropriation Requests for project funding and manage capital and operating expenses budgets.
  • Plan and implement with a team I&A manufacturing lines through development, procurement, fabrication and qualification (lean line layout, capacity planning, material procurement, build schedule management, etc.).
  • Ensure compliance with all Federal, State, local, and Company regulations, policies, and procedures as it relates to medical devices.
  • Adhere to Johnson & Johnson environmental and safety policies and guidelines.
  • Align with Johnson & Johnson Standards of Leadership (Credo Values, customer/Marketplace Focus, Innovation, Interpersonal and People Development).
Desired Qualifications
  • Black Belt certification is preferred.
  • Experience with Design of Experiments is preferred.
  • ISO 13485, ISO 14971 and relevant guidance knowledge is preferred.
  • Experience with advanced manufacturing technologies and digital solutions is preferred.
  • Experience with lean manufacturing and continuous improvement methodologies beyond basic capabilities is preferred.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Icotyde launches with 1,500 prescriptions, Guggenheim projects $14.9 billion peak sales.
  • Atraverse Medical acquisition bolsters HOTWIRE system for atrial fibrillation ablations.
  • ETHICON 4000 Stapler gains CE Mark, reducing surgical leaks costing €5,200 per case.

What critics are saying

  • Stelara sales plummet 60% to $656 million from Amgen and Samsung biosimilars.
  • Over 90,000 talc lawsuits trigger $966 million October 2025 verdict against J&J.
  • CARVYKTI manufacturing shortfalls cap multiple myeloma sales growth in 2026.

What makes Johnson & Johnson unique

  • Diversified revenue spans Innovative Medicine, MedTech, and consumer health segments.
  • DARZALEX sales hit $4 billion in Q1 2026, exceeding forecasts by $600 million.
  • CARTO System marks 30 years, powering AI-driven CARTOSOUND SONATA for electrophysiology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE